FOR IMMEDIATE RELEASE…Oct. 6, 2015…SAN DIEGO…bioTheranostics, Inc., a leader in molecular diagnostics for cancer, today announced …
BioTheranostics, Inc. is a commercial-stage molecular diagnostics company that develops and provides diagnostic, prognostic and predictive tests that support physicians in the treatment of cancer patients. Established in 2008 as a division of bioMérieux SA after its acquisition of AviaraDx, the Company is based in San Diego, CA and offers testing services through its CLIA-certified, CAP-accredited laboratory that is licensed in all 50 states. bioTheranostics is a leader in the development of evidence-based biomarkers to address unmet medical needs, and the Company has set the foundation for rapid growth.
BioTheranostics has commercialized two proprietary, highly differentiated products focused on early stage breast cancer and all metastatic cancers, Breast Cancer Index (BCI) and CancerTYPE ID (CTID), respectively. Both BCI and CTID, the proprietary component of bioT3, have obtained Medicare coverage through the Palmetto MolDx program and are supported by a robust IP portfolio. Recent milestones for the BCI growth platform include Medicare coverage in November 2014 and a very positive reception at the San Antonio Breast Conference in early December 2014.
Commercial ramp for Breast Cancer Index
Full commercial BCI launch
CTID and BCI health economics studies published
BCI obtains Medicare coverage
Key Breast Cancer Index clinical studies published
Key CancerTYPE ID clinical studies published
CancerTYPE ID obtains Medicare coverage
Commercial launch of CancerTYPE ID
AviaraDx acquired by bioMérieux and renamed bioTheranostics
CancerTYPE ID (CTID) biomarker discovery initiated
Breast Cancer Index (BCI) biomarker discovery initiated